Saturday 17 October 2026
Export CAI’s income statement to Excel — free account
Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024. In the quarter to June 2026, revenue grew 45.4%, EPS grew 100.0%, free cash flow grew 8.47% and total debt rose 5.20%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
30.56
1.20
−3.78%
Follow CAI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
47.41 | 0.00 | 0.00 | 0.00 |
+6 more quarters Free account |
P/S ratio |
5.09 | 5.57 | 5.56 | 13.75 | |
P/FCF ratio |
40.67 | 40.92 | 67.44 | 0.00 | |
P/Operating CF |
177.02 | 153.67 | 100.74 | 136.70 | |
P/B ratio |
8.52 | 8.51 | 7.81 | 17.84 | |
Price to Tangible BV |
8.81 | 8.80 | 8.09 | 18.59 | |
EV/Sales |
4.69 | 5.08 | 5.04 | 13.13 | |
EV/EBITDA |
25.78 | 32.37 | 50.81 | 0.00 | |
EV/Operating CF |
27.53 | 31.28 | 49.19 | (14,932.13) | |
EV/FCF |
37.44 | 37.34 | 61.14 | (582.10) | |
Quick Ratio |
4.75 | 6.35 | 7.17 | 9.11 | |
Current Ratio |
5.53 | 7.05 | 7.85 | 9.93 | |
Net Debt/EBITDA |
(11.85) | (34.07) | (4.51) | (9.52) | |
Debt/Assets |
31.97% | 32.83% | 33.67% | 38.24% | |
Debt/Equity |
0.66 | 0.64 | 0.66 | 0.79 | |
Asset Turnover |
0.91 | 1.56 | 1.44 | 1.26 | |
Operating CF/Net income |
(44.70) | (64.46) | 0.78 | 2.57 | |
Capex/Depreciation |
(3.23) | (1.34) | (1.04) | (0.97) | |
Interest Coverage |
2.92 | 0.41 | 7.79 | 2.42 | |
Research and Development Expense of Revenue |
12.27% | 14.49% | 10.87% | 9.97% | |
Selling, General and Administrative Expense of Revenue |
45.62% | 48.46% | 34.37% | 43.00% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
8.43% | 7.34% | 4.56% | 6.30% | |
Graham Net Nets |
0.08 | 0.09 | 0.10 | 0.04 | |
Graham Number |
4.21 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
2.11% | (42.46%) | (38.81%) | (41.85%) | |
Free Cash Flow Yield |
2.46% | 2.44% | 1.48% | (0.16%) | |
Revenue per Share |
0.93 | 0.77 | 1.75 | 0.77 | |
Operating CF per Share |
0.10 | 0.12 | 0.27 | 0.22 | |
Capex per Share |
(0.08) | (0.04) | (0.03) | (0.03) | |
Free Cash Flow per Share |
0.02 | 0.08 | 0.24 | 0.20 | |
Cash per Share |
2.80 | 2.91 | 4.79 | 2.68 | |
Shareholders Equity per Share |
2.09 | 2.10 | 3.45 | 1.70 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.09 | 2.10 | 3.45 | 1.70 | |
Free Cash Flow |
6.40 | 22.53 | 39.69 | 55.33 | |
Working Capital |
866.39 | 870.28 | 870.66 | 768.22 | |
Capital Expenditures |
(22.07) | (10.34) | (5.09) | (7.09) | |
Net Current Asset Value |
419.94 | 445.28 | 449.44 | 348.04 | |
EV/EBIT |
30.28 | 42.55 | 90.66 | 0.00 | |
Capex to Sales |
0.08 | 0.05 | 0.02 | 0.03 | |
Price to Operating Income |
32.89 | 46.63 | 100.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
83.89 | 89.38 | — | — | |
Average Payables |
57.36 | 48.80 | — | — | |
Average Inventory |
82.20 | 57.93 | — | — | |
Average Assets |
1,092.34 | 581.19 | 562.83 | 492.29 | |
Average Common Equity |
522.32 | (952.67) | — | — |
Columns are period end dates